This mechanism offers viable therapeutic options: targeted inhibition of ITLN1 (via shRNA or monoclonal antibodies) or pharmacological inhibition of CAPN2 (using calpain inhibitors such as MDL28170) significantly reduced intestinal inflammation and PANoptosis in vitro and in vivo. These effects were accompanied by the restoration of mucosal barrier integrity in colitis models. This evidence concerns the gene ITLN1 and colitis.